Wegovy vs Ozempic: what’s the difference?

Wegovy and Ozempic contain the same medicine, semaglutide, made by Novo Nordisk. What separates them is the FDA label: Wegovy is approved for weight reduction, at a maintenance dose of 2.4 mg a week, while Ozempic is approved for type 2 diabetes, at up to 2 mg. That one difference drives the dose ladder, what the trials measured, how insurance handles each, and which one a clinician prescribes for weight loss.

Here is how the two compare, with self-pay prices read from NovoCare on October 26, 2026.

Wegovy and Ozempic at a glance

Sources: the Wegovy and Ozempic labels, NovoCare Pharmacy and the CMS Bridge form.

Same molecule, different approvals

The FDA approves a product for specific uses, based on the trials behind it. Novo Nordisk ran Ozempic’s trials in adults with type 2 diabetes and measured blood sugar (HbA1c). It ran Wegovy’s trials in people with obesity or overweight and measured weight. So each label lists different uses:

• Ozempic is approved to improve blood sugar in adults with type 2 diabetes, to lower the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes and heart disease, and to lower the risk of kidney decline and kidney failure in adults with type 2 diabetes and chronic kidney disease.
• Wegovy is approved for long-term weight reduction in adults with obesity, adults with overweight and a weight-related condition, and children 12 and older with obesity. It is also approved to lower heart risk in adults with heart disease and obesity or overweight, and has an accelerated approval for MASH with moderate to advanced liver fibrosis.

Ozempic has no weight-management indication. A clinician who prescribes it for weight loss alone is prescribing off-label. For weight loss, the approved semaglutide products are the Wegovy injection and the Wegovy pill.

Two different dose ladders

Wegovy starts at 0.25 mg a week and steps up every 4 weeks through 0.5, 1 and 1.7 mg to the usual maintenance dose of 2.4 mg from week 17. Adults who have tolerated 2.4 mg for at least 4 weeks and need more weight loss can go to 7.2 mg, sold as Wegovy HD. Each dose comes in a single-dose pen, sold four to a box; 2.4 mg also comes in a FlexTouch pen that holds four doses.

Ozempic starts at 0.25 mg a week for 4 weeks, then 0.5 mg. The label allows 1 mg after at least 4 weeks on 0.5 mg, and 2 mg after at least 4 weeks on 1 mg, only if blood sugar control needs it. The maximum is 2 mg. Each pen holds a month of weekly doses.

Both brands also come as daily pills, and they are not the same pill. The Wegovy pill goes from 1.5 mg to 25 mg for weight loss. Ozempic tablets come in 1.5, 4 and 9 mg for type 2 diabetes (label). Our semaglutide page covers every form.

You can’t take the two together. The Wegovy label says not to combine it with other semaglutide products or any other GLP-1 medicine.

What the trials measured

Wegovy’s trials report weight change in percent; Ozempic’s report it in kilograms, as a secondary result next to blood sugar. These are separate trials with different people, doses and lengths, so read each against its own placebo.

Scroll sideways to see the full table

Sources: Wegovy label (Studies 2 and 3) and Ozempic label (Tables 3 and 7).

In the 30-week Ozempic trial, HbA1c fell 1.4 points on 0.5 mg and 1.6 on 1 mg, against 0.1 on placebo. Going from 1 mg to 2 mg added 0.8 kg of weight loss over 40 weeks, a difference the label calls not statistically significant. People with type 2 diabetes also lost less on Wegovy than people without it: 9.6% against 14.9%.

For how semaglutide compares with tirzepatide, the drug in Zepbound, see Wegovy vs Zepbound and Zepbound vs Ozempic.

Side effects

Stomach side effects lead on both labels and are most common while the dose is rising. The rates below come from different trials, so compare each drug with its own placebo column.

Scroll sideways to see the full table

Wegovy’s rates come from three weight-loss trials of up to 68 weeks; Ozempic’s from two diabetes trials with an average of about 33 weeks on the drug. Both carry a boxed warning for thyroid C-cell tumors, and neither is for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Both labels warn about pancreatitis, gallbladder disease, low blood sugar with insulin or sulfonylureas, kidney injury from dehydration and severe stomach problems. Our GLP-1 side effects guide and Wegovy side effects guide go further.

Why insurers treat them differently

Coverage follows the approved use, not the molecule. Medicare spells this out on its GLP-1 Bridge form: a prescription for type 2 diabetes, heart-risk reduction, sleep apnea or MASH goes to your regular Part D plan. A prescription to reduce body weight, without one of those diagnoses, goes through the Medicare GLP-1 Bridge, which charges $50 a month from July 1, 2026 to December 31, 2027. The Bridge lists Wegovy injections, tablets and HD; it doesn’t list Ozempic.

Commercial plans decide for themselves whether to cover weight-loss drugs, and the answer can change at renewal. Check your plan’s drug list for the reason you’re being prescribed; our insurance guide lists the questions to ask, and our Medicare guide covers the Bridge.

The makers’ savings offers follow the same split. With commercial coverage, NovoCare’s offers can bring either drug to as little as $25 a month, with savings capped at $100 a month, and people with government insurance can’t use them. The Ozempic offer asks how your type 2 diabetes is being treated when you register.

What each costs in October 2026

These are NovoCare Pharmacy’s self-pay prices for one month, read on October 26, 2026.

Self-pay, Ozempic costs no less than Wegovy: the same $349 at most doses, and $499 at Ozempic’s 2 mg dose against $349 for Wegovy 2.4 mg. With commercial insurance that covers the drug, the savings offers above apply instead. Our Wegovy cost guide and Wegovy coupon guide go dose by dose, and our brand-name GLP-1 rankings and semaglutide rankings compare programs that prescribe Wegovy.

Which one fits you

• If weight loss is the goal and you don’t have type 2 diabetes, Wegovy is the semaglutide product approved for it.
• If you have type 2 diabetes, your clinician may prescribe Ozempic for blood sugar, and its heart and kidney indications apply to you.
• If you have heart disease and obesity or overweight, Wegovy carries a heart-risk indication; Ozempic’s applies to adults with type 2 diabetes.
• If you’re 12 to 17, Wegovy is approved for teens with obesity; Ozempic is approved for adults.
• If you’d rather not inject, the Wegovy pill is the daily option approved for weight loss.

A licensed clinician can weigh these against your history and coverage. Our match tool finds programs that prescribe Wegovy.

The bottom line

Wegovy and Ozempic are both semaglutide, but Wegovy is the one approved and dosed for weight loss, up to 2.4 mg a week or 7.2 mg for some adults, while Ozempic treats type 2 diabetes at up to 2 mg. As of October 2026, both pens cost $349 a month self-pay after the starter fills, so Ozempic isn’t a cheaper way to the same result. Insurance pays according to the approved use, so check your plan for the reason you’re being prescribed. More options on our weight-loss hub.